Solana setup hints at relief rally before major move
Solana remains in a cautious consolidation phase as traders wait for a clearer signal on the token’s next major direction.
Solana remains in a cautious consolidation phase as traders wait for a clearer signal on the token’s next major direction.
Ethereum remains under market pressure in 2026, but analysts say its long-term investment case continues to draw support from onchain data.
Ghana has introduced a new crypto law as regulators move to bring faster oversight to the country’s growing digital asset market.
The U.S. Food and Drug Administration (FDA) has approved Datroway (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Agios Pharmaceuticals (NASDAQ:AGIO) announced that the European Commission has granted marketing authorization for Pyrukynd (mitapivat) to treat anemia in adult patients with alpha- or beta-thalassemia.
Imperial Petroleum (NASDAQ:IMPP) announced its financial and operational results for the first quarter of 2026, marking the second-best quarterly performance in the ship-owning company’s history.
Functional Brands (NASDAQ:MEHA) announced it has signed a definitive agreement to acquire the Alchemy gold-backed blockchain settlement and decentralized finance (DeFi) platform from BullionFX.
Quanta Services (NYSE:PWR) announced today that its board of directors has authorized a new $1 billion stock repurchase program and declared its latest quarterly cash distribution.
Assembly Biosciences (NASDAQ:ASMB) announced plans to expand the clinical development framework for its experimental compound ABI-6250, pushing the asset beyond its initial virology target into chronic cholestatic liver conditions.
Enhertu (trastuzumab deruxtecan) moved a step closer to a milestone regulatory approval in Europe, securing a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) as a tumor-agnostic treatment for advanced solid malignancies.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
